HDM1005
Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
Huadong Medicine · Phase 2 · Recruiting · Enrollment 240
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| HDM1005 dose cohort 1 QW | n/r | n/r | n/r | n/r |
| HDM1005 dose cohort 2 QW | n/r | n/r | n/r | n/r |
| HDM1005 dose cohort 3 QW | n/r | n/r | n/r | n/r |
| HDM1005 dose cohort 4 QW | n/r | n/r | n/r | n/r |
| placebo QW | n/r | n/r | n/r | n/r |
Not shown
- HDM1005 dose cohort 1 QW: endpoint not reported
- HDM1005 dose cohort 2 QW: endpoint not reported
- HDM1005 dose cohort 3 QW: endpoint not reported
- HDM1005 dose cohort 4 QW: endpoint not reported
- placebo QW: endpoint not reported